Maegim

Stock search

Search by company name, 6-digit code, or Korean initials (e.g. ㅅㅅㅈㅈ)

☆한국어

HLB PHARMACEUTICAL CO., LTD.

HLB제약047920KOSDAQSector: Pharma & Biotech
₩7,6103.30%Market cap ₩249.6BAs of Sep 7, 2026 close · updated once daily
Market cap
₩249.6B
#328 in KOSDAQ
56.5x
Sector median 15.7x (profitable cos.)
2.06x
Sector median 1.59x
0.0%
Sector median 0.0%
B
Grade B55.5 ptsTop 43% of 2,522 graded stocksMethodology v2.0
Financial strength
60.1/100
Price attractiveness
52.9/100
Shareholder Return
37.5/100

As of Sep 7, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

How to read this grade
SABCurrentCDF

Toward S means a higher total-score band; toward F, a lower band. Badges are distinguished by ink intensity and shape (fill, outline, dashed) — never by hue.

Maegim maps a total score — built from sector-relative percentile scoring — onto fixed, predefined thresholds to assign one of six bands, S to F. This stock is scored by the same formula as all 2,522 graded stocks and is currently in band B with a total score of 55.5 points.

How grades are computed →What grades do and don’t mean →What the grade does not reflect →

ⓘ Growth momentum not rated — will be included automatically as data accumulates

1-year closing price

Loading closing price history…
 
Low ₩5,686High ₩19,260
Latest close
Price change by period
1W
7.00%
1M
9.20%
3M
26.90%
1Y
41.60%

Adjusted for 1 price-basis change(s) such as stock splits or reverse splits during the period.

As of the Sep 7, 2026 close · updated once daily · a factual record computed from closing prices only; dividends are not included, and this is not a buy or sell signal.

1

Financial strength

60.1/100
How much debt does it carry relative to equity?
36.4%
Sector median 51.6%
Sector lowhighTop 32.6% in sector
Can it cover what's due within a year?
193.6%
Sector median 191.7%
Sector lowhighTop 48.4% in sector
How much of revenue becomes profit?
0.5%
Sector median -2.4%
Sector lowhighTop 46.5% in sector
How much did it earn on its own capital?
3.7%
Sector median -4.5%
Sector lowhighTop 32.2% in sector

Source filing: annual report (consolidated) — view original ↗

3

Price attractiveness

52.9/100
Is the price expensive relative to earnings?
56.5x
Sector median P/E of profitable peers 15.7x · 58% loss-making
Sector lowhighTop 35.8% in sector
Is the price expensive relative to book value?
2.06x
Sector median 1.59x
Sector lowhighBottom 41.5% in sector

Valuation uses the Sep 7, 2026 close and market cap

4

Shareholder Return

Single-indicator axis37.5/100
Does the company actually pay dividends?
0.0%
Sector median 0.0%
Sector lowhighBottom 37.5% in sector

Dividends & treasury shares

Treasury shares (FY2025)
581 shares (0.0% of shares issued)

Source: annual report (DART) — dividend allocation & total shares

Source filing: annual report (consolidated) — view original ↗

Financial checklist

Based on the FY2025 annual report · year-over-year comparison · determined on Sep 7, 2026

Of 9 items: 2 met · 2 not met · 5 not computable

Not metMetNot computable

Positive net income
Whether net income (attributable to owners where available) is above zero.
Met
₩4.6B
Positive operating cash flow
Whether cash flow from operations is above zero.
Met
₩569M
Return on assets up
Whether net income over beginning total assets rose from the prior year.
Not computable

Not compared — the reporting basis (consolidated/separate) changed within the comparison period

Operating cash flow exceeds net income
Whether operating cash flow is greater than net income.
Not met
₩569M vs ₩4.6B
Liabilities-to-assets ratio down
Whether total liabilities as a share of total assets fell from the prior year.
Not computable

Not compared — the reporting basis (consolidated/separate) changed within the comparison period

Current ratio up
Whether current assets over current liabilities rose from the prior year.
Not computable

Not compared — the reporting basis (consolidated/separate) changed within the comparison period

Shares outstanding not increased
Whether common shares issued did not increase from the prior year. Increases from bonus issues and stock dividends are also counted.
Not met
31,814,994 → 32,799,356
Operating margin up
Whether operating income over revenue rose from the prior year.
Not computable

Not compared — the reporting basis (consolidated/separate) changed within the comparison period

Asset turnover up
Whether revenue over beginning total assets rose from the prior year.
Not computable

Not compared — the reporting basis (consolidated/separate) changed within the comparison period

A record of facts determined by fixed rules from the financial statements in the latest annual report. Not used in grading, and not a buy or sell signal. Source filing: annual report (consolidated) — view original ↗

Grade change history

Jul 23, 2026B

Methodology version change (v2.0 applied)

Jul 15, 2026BVersion v1

First calculation

Grade changes are a factual record produced from public data by a fixed formula; they do not signal future changes.

Recent filings for this stock

Last 120 days · monitored filing types only
Paid-in capital increaseSep 8, 2026Source ↗
Periodic report filedAug 13, 2026Source ↗
Periodic report filedMay 13, 2026Source ↗

View in the filings calendar →